Studies have shown that in the development model for hepatitis B cirrhosis, the model of Child–Pugh (C–P) score, the model of end-stage liver disease score, and the five-stage prognostic system are the main risk-assessment methods for determining the disease severity and prognosis of cirrhosis patients. The first two methods cannot effectively predict the prognosis of cirrhosis patients because of the presence of considerable subjectivity, the fact that specific objective indices may be influenced by many factors, failure to assess the effects of the severe complications of portal hypertension on the prognosis, and other limitations [4,5]. The five-stage prognostic system includes clinically closely related portal hypertension and its complications on the basis for staging, which is consistent with the disease progression of cirrhosis and the development of portal hypertension and complications reported by a relevant study [6]. Although several of the aforementioned methods can reflect changes in the condition of the cirrhosis to a certain extent, they cannot provide assessments through specific numerical values. Therefore, it is particularly important to explore a method to quantitatively evaluate cirrhosis complications and their severity.

Technetium phytate (99mTc-Phy), chelated with the calcium ions in the blood to form 99mTc-calcium phytate

Objective The aim was to perform exploratory research on the application of technetium phytate (99mTc-Phy) portal perfusion index (PPI) imaging in predicting the complications of hepatitis B cirrhosis and their severity.

Patients and methods A total of 65 hepatitis B cirrhosis patients were stratified, respectively, into three groups from classes A to C according to Child–Pugh scores and five groups from stages 1 to 5 according to the five-stage prognostic system. PPIs were compared and analyzed, respectively, among the three and five groups. The correlations between PPIs and major biochemical indices of liver function were also analyzed. One-way analysis of variance was used to compare the PPIs among the various groups and a nonparametric Spearman test was used to analyze the correlations between PPIs and various biochemical indices.

Results PPIs of the five groups decreased gradually from stage 1 to stage 5 (73.03 ± 8.49, 52.96 ± 16.22, 46.24 ± 15.25, 29.99 ± 17.36, and 11.50 ± 6.37, respectively); with the exception of the difference between stages 2 and 3 (P = 0.252), the differences between the remaining groups were statistically significant (P < 0.05). The PPI showed positive correlations with serum total protein, serum albumin, and albumin/globulin results (r = 0.292, 0.559, 0.520, respectively; P < 0.05), and negative correlations with serum globulin (r = −0.366, P < 0.05).

Conclusion Technetium phytate PPI could be a promising noninvasive and effective method for predicting the complications of hepatitis B cirrhosis and their severity; a lower PPI value indicates a higher severity of complications for hepatitis B cirrhosis patients. PPI can provide very meaningful reference data for clinical practice. Nucl Med Commun 39:818–824 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords: complications, hepatic portal perfusion index, hepatitis B cirrhosis, nuclide imaging

Introduction China is a major country for chronic hepatitis B (hereafter referred to as hepatitis B). During the course of disease development, hepatitis B can progress to cirrhosis, with the proportion of cirrhosis that eventually progresses to liver cancer also being relatively high. Some studies have shown that in the development model for hepatitis B–cirrhosis–liver cancer, the probability of cirrhosis progressing to primary liver cancer is as high as 9.2–28.6% [1,2]. Cirrhosis patients often have many complications. In particular, patients with decompensated cirrhosis have a rather high mortality rate [3]. At present, the Child–Pugh (C–P) score, the model of end-stage liver disease score, and the five-stage prognostic system are the main risk-assessment methods for determining the disease severity and prognosis of cirrhosis patients. The first two methods cannot effectively predict the prognosis of cirrhosis patients because of the presence of considerable subjectivity, the fact that specific objective indices may be influenced by many factors, failure to assess the effects of the severe complications of portal hypertension on the prognosis, and other limitations [4,5]. The five-stage prognostic system includes clinically closely related portal hypertension and its complications on the basis for staging, which is consistent with the disease progression of cirrhosis and the development of portal hypertension and complications reported by a relevant study [6]. Although several of the aforementioned methods can reflect changes in the condition of the cirrhosis to a certain extent, they cannot provide assessments through specific numerical values. Therefore, it is particularly important to explore a method to quantitatively evaluate cirrhosis complications and their severity.

Technetium phytate (99mTc-Phy), chelated with the calcium ions in the blood to form 99mTc-calcium phytate

Received 2 February 2018 Revised 2 May 2018 Accepted 11 May 2018

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
colloids, is the imaging agent of portal perfusion index (PPI). Normally, ~90% of the chelated complex is taken up as foreign bodies by liver Kupffer cells in phagocytosis and the rest is taken up by the mononuclear phagocytes of the spleen, lymph nodes, and bone marrow. Other $^{99m}$Tc radiolabeled agents, which are hardly taken up by liver Kupffer cells, cannot accurately present the change of liver blood [7]. The PPI provided by $^{99m}$Tc-Phy portal perfusion index imaging ($^{99m}$Tc-Phy PPI) represents a quantitative index for the proportion of hepatic portal perfusion; changes in the ratio can intuitively reflect changes in the liver blood supply. Moreover, as the severity of the cirrhosis changes, the PPI value also changes gradually [8,9]. On the basis of this, we carried out this retrospective study on the clinical data of 65 cirrhosis patients, whereby the patients were classified and categorized according to C-P scores and the five-stage prognostic system to compare changes in PPI values in various stages and to investigate the correlations of PPI with the main biochemical indices of liver function.

**Patients and methods**

**Patients**

Eligible patients were selected from among those who had undergone $^{99m}$Tc-Phy PPI imaging between April 2011 and August 2016. All of the examined patients provided their informed consent to the study. A total of 65 consecutive hepatitis B patients [50 males, 15 females; age 16–82 years (mean: 50±10 years)] were recruited retrospectively. Patients with hepatitis B cirrhosis had been diagnosed on the basis of the criteria set by the Clinical Practice Guidelines [10,11] and several laboratory parameters were measured within 2 weeks of the $^{99m}$Tc-Phy PPI examination: blood routine, biochemical indices of liver function, renal function, and hepatitis B virus.

The diagnosis of hepatitis B cirrhosis and the values of the five-stage prognostic system on the basis of the criteria set by D’Amico and colleagues [6,7,12] are as follows: stage 1: compensated cirrhosis without varices; stage 2: compensated cirrhosis with varices; stage 3: bleeding without other disease complications; stage 4: first nonbleeding decompensating event; and stage 5: any second decompensating event. The characteristics of the included patients are shown in Table 1.

**C-P score**

Points were accumulated according to whether the patients had hepatic encephalopathy, the severity of ascites, the serum total bilirubin values, the serum albumin values, and the prothrombin time values, and the patients were divided into three classes – classes A, B, and C – according to the accumulated points.

The patients were then scored on the basis of the modified C-P scoring system and divided into classes A, B, or C on the basis of the score obtained (Table 2) [13].

Table 1 shows the basic information on the hepatitis B cirrhosis patients. On classifying according to the C-P score, there were 38 patients in class A, 15 patients in class B, and 12 patients in class C; on staging according to the five-stage prognostic system, there were 12 patients in stage 1, 10 patients in stage 2, 18 patients in stage 3, 20 patients in stage 4, and five patients in stage 5. Table 3 details the basic information of staging for the 65 cirrhosis patients according to the five-stage prognostic system.

**Hepatic portal perfusion method and portal perfusion index calculation**

(a) Image acquisition: a single-photon emission computed tomography instrument (Infinia GP3; GE Medical Systems, Milwaukee, Wisconsin, USA) was used. The examinee lay supine on the examination table in a resting state. The acquisition range included the left ventricle, the liver, the kidneys, and other organs of the chest and abdomen. After a bolus injection of 185 MBq $^{99m}$Tc-Phy (provided by Hangzhou Atomic Tech Pharmaceutical Co. Ltd., Hangzhou, Zhejiang Province, China), the instrument was started up immediately to acquire images with a 64×64 matrix, a 140 KeV energy peak, and a 10% energy window that collected one frame every second for 60 s.

| Sex (male/female) | Mean ± SD or frequency (%) | Median (range) |
|-------------------|---------------------------|---------------|
| Age (years)       | 50 ± 10                   | 50 (16–82)    |
| Laboratory tests  |                           |               |
| TP (g/l)          | 66.89 ± 6.97              | 66.3 (47.6–78.8) |
| Alb (g/l)         | 37.33 ± 8.17              | 37.2 (20.1–50.7) |
| GlcB (g/l)        | 29.55 ± 6.91              | 28.3 (13.7–44.9) |
| A/G               | 1.37 ± 0.53               | 1.4 (0.4–2.5)  |
| AST (U/l)         | 40.72 ± 63.92             | 24 (4–482)     |
| ALP (U/l)         | 47.31 ± 66.60             | 31 (6–516)     |
| TP (l)            | 89.91 ± 37.15             | 83.5 (27–202)  |
| TB (μmol/l)       | 37.19 ± 60.71             | 20 (8–421.9)   |
| DB (μmol/l)       | 20.14 ± 40.03             | 7 (2–264)      |
| IB (μmol/l)       | 17.05 ± 21.17             | 12 (3–158)     |
| PT (s)            | 14.36 ± 2.80              | 13.4 (11.1–28.4) |
| Child–Pugh score  | 6.69 ± 2.10               | 6 (5–12)       |
| PPI               | 44.55 ± 22.78             | 47.4 (1.8–84.2) |

A/G, albumin/globulin; Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DB, direct bilirubin; GloB, globulin; IB, indirect bilirubin; PPI, portal perfusion index; PT, prothrombin time; TB, total bilirubin; TP, total protein.

Table 2 Child–Pugh classification of cirrhosis patients

| Clinical and laboratory criteria | Points |
|---------------------------------|--------|
| Encephalopathy                  | 1      |
| Ascites                         |        |
| Total bilirubin (μmol/l)        |        |
| Albumin (g/l)                   |        |
| Prothrombin time (S)            |        |
| Points                          | 2      |
|                                 |        |
|                                 | 3      |
| Encephalopathy                  | None   |
| Ascites                         | None   |
| Total bilirubin (μmol/l)        | <34    |
| Albumin (g/l)                   | >35    |
| Prothrombin time (S)            | <4    |
| Points                          | 2      |
|                                 |        |
|                                 | 3      |
| Encephalopathy                  | Mild to moderate (grade 1 or 2) |
| Ascites                         | Mild to moderate (diuretic responsive) |
| Total bilirubin (μmol/l)        | 34–51  |
| Albumin (g/l)                   | 28–35  |
| Prothrombin time (S)            | 4–6    |
| Points                          | 3      |
|                                 |        |
|                                 | 4      |
| Encephalopathy                  | Severe (grade 3 or 4) |
| Ascites                         | Severe (diuretic refractory) |
| Total bilirubin (μmol/l)        | >51    |
| Albumin (g/l)                   | <28    |
| Prothrombin time (S)            | >6     |
| Points                          | 4      |
|                                 |        |
|                                 | 5      |

Class obtained by adding the score for each parameter (total points): Class A, 5–6 points (least severe); class B, 7–9 points (moderate severe liver disease); class C, 10–15 points (most severe liver disease).
### Table 3: Characteristics of 65 patients in different stages on the basis of the five-stage prognostic system

| Stages | N   | Male | Female | Age      | PPI       | Child–Pugh classes |
|--------|-----|------|--------|----------|-----------|--------------------|
|        |     |      |        |          |           | A | B | C |
| Stage 1| 12  | 9    | 3      | 43 ± 12  | 73.03 ± 8.49 | 11 | 1 | 0 |
| Stage 2| 10  | 5    | 5      | 52 ± 6   | 52.96 ± 16.22| 10 | 0 | 0 |
| Stage 3| 18  | 14   | 4      | 56 ± 8   | 46.24 ± 15.25| 7  | 7 | 4 |
| Stage 4| 20  | 18   | 2      | 49 ± 10  | 29.99 ± 17.36| 10 | 5 | 5 |
| Stage 5| 5   | 4    | 1      | 51 ± 13  | 11.50 ± 6.37 | 0  | 2 | 3 |
| Total  | 65  | 50   | 15     | 50 ± 10  | 44.55 ± 22.78| 38 | 15| 12 |

PPI, portal perfusion index.

### Results

#### Correlations between portal perfusion index and the main biochemical indices

The PPI of the 65 cirrhosis patients showed positive correlations with serum total protein, serum albumin, and albumin/globulin results (respectively, \( r = 0.292, P < 0.05; r = 0.559, 0.520, P < 0.01 \)) and negative correlations with serum globulin, aspartate aminotransferase, alkaline phosphatase, and direct bilirubin results (respectively, \( r = -0.366, P < 0.05; r = -0.197, -0.165, \) and \(-0.025, P > 0.05; \) Table 4).

#### Comparison of portal perfusion indexes between all staged groups in the five-stage prognostic system

According to the five-stage prognostic system, the 65 cirrhosis patients could be divided into five groups. Their PPI mean values were, respectively, 73.03 ± 8.49, 52.96 ± 16.22, 46.24 ± 15.25, 29.99 ± 17.36, and 11.50 ± 6.37; as the staging level increased, the PPI mean value decreased significantly. The PPIs between all groups were compared separately, and there were significant differences between stages 1 and 2, stages 1 and 3, stages 1 and 4, stages 1 and 5, stages 2 and 4, stages 2 and 5, stages 3 and 4, stages 3 and 5, and stages 4 and 5, with \( P \) less than 0.05; there was no statistically significant difference between stages 2 and 3 (\( P = 0.252; \) Fig. 2).

#### Comparison of biochemical indices between all staged groups in the five-stage prognostic system

Serum total protein showed a significant difference between stages 2 and 3 (mean difference = 6.31, \( P < 0.05 \)). Serum albumin showed significant differences between stages 2 and 3 (mean difference = 8.11, \( P < 0.05 \)) and between stages 4 and 5 (mean difference = 8.08, \( P < 0.05 \)). Albumin/globulin showed significant differences between stages 1 and 2 (mean difference = 0.44, \( P < 0.05 \)) and between stages 4 and 5 (mean difference = 0.50, \( P < 0.05 \)). Alkaline phosphatase showed a significant difference between stages 4 and 5 (mean difference = −50.65, \( P < 0.05 \)). There were no significant differences between stages 2 and 3 (mean difference = 2.25, \( P > 0.05 \)).
differences in the comparisons of all adjacent stages for all the remaining indices (Table 5).

**Comparison of portal perfusion indexes between all groups classified by C-P scores**

According to the C-P scoring criteria, the 65 cirrhosis patients could be divided as follows: 39 patients in class A, 15 patients in class B, and 11 patients in class C. Their PPI mean values were, respectively, %, 52.26 ± 20.48, 36.77 ± 20.88, and 27.80 ± 22.03. As the classification level increased, the PPI mean value decreased significantly. The PPIs between all groups were compared separately, and there were significant differences between classes A and B and between classes A and C, with $P$ less than 0.05. There was no statistically significant difference between classes B and C ($P = 0.282$; Fig. 3).

**Discussion**

Hepatitis B cirrhosis is often complicated with hepatic fibrosis and hepatocellular damage. These pathological
changes generally affect hepatic hemodynamic changes [17,18], among which changes in portal venous and hepatic arterial hemodynamics are most able to reflect changes in liver function [19,20]; the hepatic PPI can intuitively reflect the proportion of liver blood supply. Therefore, in this paper, hepatitis B cirrhosis patients were categorized according to the C-P classification and the five-stage prognostic system staging to compare PPI changes between all classes and all stages, and to analyze the correlations between the patients’ PPIs and their main biochemical indices.

The PPI value can be determined using the $^{99m}$Tc-Phy PPI method. The quantitative determination of the two components of hepatic blood flow is based on the following assumption: the time in which a substance injected intravenously through a ‘bolus’ injection reaches the liver is not the same [7,12,13]. Before portal venous perfusion appears, the $^{99m}$Tc-calcium phytate colloids that went through the hepatic artery have already arrived at the liver. Before hepatic artery recirculation appears, all $^{99m}$Tc-calcium phytate colloids that went through the portal vein have already arrived at the liver [8]. Previous published work has used the method of mathematical modeling to verify the aforementioned hypothesis, and its results were close to the true hepatic blood flow shunt changes [17]. Other work reported on the use of PPI to study the relationship between hepatic perfusion and ascites in cirrhosis patients; as the hepatic portal vein perfusion decreased, the severity of ascites increased gradually [18]. However, in hepatic perfusion with multislice spiral computed tomography, PPI of patients with cirrhosis were significantly lower compared with the control group [21]. Similarly, noncontrast MRI techniques showed that the portal vein blood volume that flows into the intrahepatic volume in one and two cardiac cycles is significantly lower in portal hypertension patients than in healthy volunteers [22].

This study is the first to use PPI to detect changes in the proportion of liver blood supply in hepatitis B cirrhosis, which is an innovative use of a repeatable and quantitative nuclear medical imaging method and is useful for the intuitive assessment and prediction of hepatitis B cirrhosis complications and their severity.

### Table 4 Correlations between portal perfusion index and the main biochemical indices ($N = 65$)

| Biochemical indices | Result $\pm$ SD | Correlation ($r$ value) | Significance ($P$ value) |
|---------------------|-----------------|-------------------------|--------------------------|
| TP                  | $66.89 \pm 6.97$ | 0.292*                  | 0.018                    |
| Alb                 | $37.34 \pm 8.17$ | 0.559**                 | <0.001                   |
| GloB                | $29.55 \pm 6.91$ | $-0.366^{**}$           | 0.003                    |
| A/G                 | $1.37 \pm 0.53$  | 0.520**                 | <0.001                   |
| AST                 | $473.1 \pm 66.60$| $-0.197$                | 0.115                    |
| ALP                 | $89.91 \pm 37.15$| $-0.165$                | 0.189                    |
| DB                  | $20.14 \pm 40.13$| $-0.025$                | 0.841                    |

A/G, albumin/globulin; Alb, albumin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; DB, direct bilirubin; GloB, globulin; TP, total protein.

*Shows significant correlation at the 0.05 level.

**Shows significant correlation at the 0.01 level.

**Fig. 2**

Portal perfusion index in different stages on the basis of the five-stage prognostic system; as the staging level increased, the portal perfusion index mean value decreased significantly. PPI, portal perfusion index.
Table 5 Characteristics of the main biochemical indices in different stages on the basis of the five-stage prognostic system

| Biochemical indices | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 |
|---------------------|---------|---------|---------|---------|---------|
| TP (g/l)            | 70.55±6.60 | 72.10±5.78 | 65.79±7.28 | 64.30±5.48 | 61.88±6.65 |
| Alb (g/l)           | 46.18±3.68  | 42.72±5.30 | 34.61±6.74 | 34.52±6.70 | 26.44±5.72 |
| GluB (g/l)          | 24.38±4.04  | 29.38±5.93 | 31.18±6.91 | 29.81±7.26 | 35.44±7.13 |
| A/G                 | 1.94±0.27   | 1.50±0.38 | 1.21±0.52 | 1.26±0.49 | 0.76±0.30  |
| ALT (U/l)           | 76.67±13.02 | 27.90±23.23 | 35.33±42.04 | 32.90±30.17 | 30.80±16.57 |
| AST (U/l)           | 45.08±41.62 | 29.00±21.17 | 43.78±37.83 | 58.30±108.92 | 50.00±31.87 |
| ALP (U/l)           | 91.50±41.44 | 77.70±42.46 | 86.78±25.89 | 86.15±30.64 | 136.80±52.49 |
| TB (μmol/l)         | 30.86±47.15 | 22.60±7.26 | 54.44±98.06 | 30.20±41.91 | 47.84±33.86 |
| DB (μmol/l)         | 14.92±31.90 | 7.20±2.20  | 31.94±83.04 | 16.80±29.65 | 29.40±21.80 |
| IB (μmol/l)         | 15.75±15.57 | 15.40±5.82 | 22.50±35.31 | 13.40±12.68 | 18.40±12.34 |

A/G, albumin/globulin; Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DB, direct bilirubin; GloB, globulin; IB, indirect bilirubin; PPI, portal perfusion index; PT, prothrombin time; TB, total bilirubin; TP, total protein.

Fig. 3

Portal perfusion index in different groups on the basis of the Child–Pugh classification; as the classification level increased, the portal perfusion index mean value decreased significantly. PPI, portal perfusion index.

Major biochemical indices of liver function, such as serum total protein, serum albumin, serum globulin, albumin/globulin, aspartate aminotransferase, alkaline phosphatase, and direct bilirubin, can all well reflect the states of liver protein synthesis, amino acid metabolism, bilirubin metabolism, and other functions [23]. In this experiment, the PPI showed positive correlations with serum total protein, serum albumin, and albumin/globulin and negative correlations with aspartate aminotransferase, alkaline phosphatase, and direct bilirubin, indicating that PPI is closely related to changes in liver function. As the PPI decreases gradually, liver function would also worsen, and vice versa. On comparing the PPI values of all stages with each other in the five-stage prognostic system, with the exception of no significant difference between stages 2 and 3, the PPIs between all other stages showed significant differences. The exception of no significant difference between stages 2 and 3 needs to be confirmed in a future study. This finding indicates that PPI also has a relatively good correlation with the five-stage prognostic system. As the staging level increased, the PPI showed a gradually decreasing trend. In addition, PPI is useful for separate assessments of changes in cirrhosis severity in the compensated period (stage 1 vs. stage 2) and the decompensated period (stages 3, 4, and 5). On comparing the main biochemical indices of all stages in the five-stage prognostic system, serum total protein and serum albumin showed significant differences between stages 2 and 3, which just so occur to be the boundary between the compensated period and the decompensated period for cirrhosis. The two indices of serum total protein and serum albumin may help distinguish compensated and decompensated cirrhosis. Whether the determination of these two indices is complementary with the PPI examination still requires thorough research with large amounts of sample data.

For the comparison of the PPIs between all groups in the C-P classification, significant differences were found between classes A and B and between classes A and C, suggesting that there is a relatively good correlation between PPI and C-P classification; as the classification level increased, the PPI showed a decreasing trend. This study found that there was no significant difference in the PPIs between classes B and C (P=0.282). This interesting phenomenon requires further thorough research with a large sample size. With increases in the C-P classification level and the five-stage prognostic system staging level, cirrhosis complications and the severity also increase gradually [24]. This study included only 65 hepatitis B cirrhosis patients; thus, the inadequate sample size can be considered a limitation. In addition, the literature has reported that serum hyaluronic acid, laminin, type III procollagen, and type IV collagen may have better applications in the assessment of hepatic fibrosis severity [9]. We will perform in-depth comparisons of those indices in our future study.

In summary, 99mTc-Phy PPI can function as a non-invasive nuclear medical examination method to non-invasively and effectively predict the complications of hepatitis B cirrhosis and their severity. A lower PPI indicates a higher severity of complications for hepatitis B cirrhosis patients.
Acknowledgements

Ning-Hu Liu wrote the main manuscript text; Meng-Jie Dong and Jun-Hui Sun amended the manuscript; Hao Liu performed the statistical analysis; Xi-Li Lu, Dan Tian, Jun Zhang, Jun Yang, Li-Hua Wu, Jian-Li Bi, and Bo Zhang collected data.

This article was funded by the National Natural Science Foundation of China (No. 81471704, 81771884), the Zhejiang Provincial Natural Science Foundation of China (No. LZ18H180007), and the Zhejiang Provincial Natural Science Foundation of China (No.LYZ18H180001).

Conflicts of interest

There are no conflicts of interest.

References

1. Liang Z, Chen Z, Li W. The value of MR diffusion weighted imaging in differential diagnosis between ovarian cystadenocarcinoma and cystadenoma. Chin J CT MRI 2015; 3:93–96.
2. Zou B, Meng L, Wu Q. Value of MR diffusion weighted imaging and CT perfusion imaging in diagnosis and classification of liver cirrhosis. J Pract Radiol 2013; 29:933–936.
3. Zeng B, Chen L, Zhang N. Comparative study on liver specific multiple organ failure score in predicting short-term mortality for HBV related cirrhosis patients with acute decompensation. Chin J Gastroenterol 2015; 20:261–266.
4. Li Q, Wang B, Jia J. The evolution and characteristics of liver function classification: from Child to MELD. Chin J Hepatol 2004; 12:319–320.
5. Li J, Lu L. Progress of model for end-stage liver disease in the value of prognostic evaluation in patients with cirrhosis. J Clin Hepatol 2011; 21:132–135.
6. D’Amico G. Esophageal varices: from appearance to rupture; natural history and prognostic indicators. In: Groszmann RJ, Bosch J, editors. Portal hypertension in the 21st century. Dordrecht: Kluwer; 2004. pp. 147–154.
7. Garcia-Tsao G, D’Amico G, Abraldes JG. Predictive models in portal hypertension. In: de Franchis R, editor. Portal hypertension Proceedings of the fourth international consensus workshop on methodology of diagnosis and treatment. Oxford: Blackwell Publishing; 2006. pp. 47–100.
8. Xiang R, Zhang H, Gu Z. The significance of the portal perfusion index of patients with cirrhosis to Child-Pugh classification. Chin J Nuclear Med 1996; 16:269.
9. Zhang J, Zhu Y. Combined serum fibrosis index and portal perfusion index to evaluate chronic hepatitis B and cirrhosis. Chin J Infect Dis 2012; 30:376–377.
10. Chinese Association for the Study of the Liver, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67:370–398.
11. Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association, Diagnostic Criteria for Chronic Hepatitis B, 2015. Chin J Integrated Traditional and Western Medicine on Liver Diseases 2015; 29:384–386.
12. D’Amico G. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014; 39:1180–1193.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transsection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646–648.
14. Tan T. Clinic of nuclear medicine. Beijing, China: People’s Medical Publishing House; 1993. pp. 653–656.
15. Bi G, Li Z. Construction of hepatic blood flow model and measurement of ITS shunt index. Chin J Biomed Engg 2010; 29:132–135.
16. El-Khalily H, Hoeffken H. Hepatic perfusion scintigraphy: relationship of liver perfusion and ascites in patients with liver cirrhosis. Chin Nucl Med 1996; 21:132–135.
17. Meng Q, Lv L, Yang B, Fu N, Lu G. Fluctuating portal velocity tracing with color doppler ultrasonography in preclinical HRS. Chin Gene Prac 2010; 13:4164–4166.
18. Meng Q, Lv L, Yang B, Fu N, Lu G. Fluctuating portal velocity tracing with color doppler ultrasonography in preclinical HRS. Chin Gene Prac 2010; 13:4164–4166.
19. Meng Q, Lv L, Yang B, Fu N, Lu G. Fluctuating portal velocity tracing with color doppler ultrasonography in preclinical HRS. Chin Gene Prac 2010; 13:4164–4166.
20. Robles O, Marin H, Fernandez H, Sanchez Bueno F, Ramirez Romero P, Pastor PP, Parrilla P. Delayed right hepatic artery hemorrhage after iatrogenic gallbladder biliary paraprosthetic cholecystectomy that required a liver transplant due to acute liver failure: clinical case and review of the literature. Cir Esp 2011; 89:670–676.
21. Shi LJ, Tian JM, Wang PJ, Bi YM, Tian J, Li SP, Li YL. Pilot study on clinical application of hepatic perfusion with multi-slice spiral CT. Chin J Hepatol 2003; 11:522–525.
22. Aguirre-Reyes DF, Sotelo JA, Arab JP, Arrese M, Tejos R, Irrazaviz P, et al. Intrahepatic portal vein blood volume estimated by non-contrast magnetic resonance imaging for the assessment of portal hypertension. Magn Reson Imaging 2015; 33:970–977.
23. Song G. Liver function-clinical significance of serumenzyme testing. J Clin Hepatol 2003; 19:195–197.
24. Tian Y, Hu N. Value of five-stage prognostic system in predicting short-term outcome of patients with liver cirrhosis. J Clin Hepatol 2015; 31:387–391.